530
Views
5
CrossRef citations to date
0
Altmetric
Review article

Noninvasive prenatal testing for congenital heart disease – cell-free nucleic acid and protein biomarkers in maternal blood

, &
Pages 1044-1050 | Received 15 Jan 2018, Accepted 02 Aug 2018, Published online: 10 Sep 2018

References

  • Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–ee603.
  • Gilboa SM, Salemi JL, Nembhard WN, et al. Mortality resulting from congenital heart disease among children and adults in the United States, 1999–2006. Circulation. 2010;122:2254–2263.
  • Dearani JA, Mavroudis C, Quintessenza J, et al. Surgical advances in the treatment of adults with congenital heart disease. Curr Opin Pediatr. 2009;21:565–572.
  • Nelle M, Raio L, Pavlovic M, et al. Prenatal diagnosis and treatment planning of congenital heart defects – possibilities and limits. World J Pediatr. 2009;5:18–22.
  • Bonnet D, Coltri A, Butera G, et al. Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality. Circulation. 1999;99:916–918.
  • Tworetzky W, McElhinney DB, Reddy VM, et al. Improved surgical outcome after fetal diagnosis of hypoplastic left heart syndrome. Circulation. 2001;103:1269–1273.
  • Franklin O, Burch M, Manning N, et al. Prenatal diagnosis of coarctation of the aorta improves survival and reduces morbidity. Heart. 2002;87:67–69.
  • Hunter LE, Simpson JM. Prenatal screening for structural congenital heart disease. Nat Rev Cardiol. 2014;11:323–334.
  • Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007;115:2995–3014.
  • Nayak K, Chandra GSN, Shetty R, et al. Evaluation of fetal echocardiography as a routine antenatal screening tool for detection of congenital heart disease. CardioVasc Diagn Ther. 2016;6:44–49.
  • Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids – a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007;581:795–799.
  • van der Vaart M, Pretorius PJ. The origin of circulating free DNA. Clin Chem. 2007;53:2215.
  • Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998;62:768–775.
  • Turchinovich A, Cho WC. The origin, function and diagnostic potential of extracellular microRNA in human body fluids. Front Genet. 2014;5:30.
  • Richards AA, Garg V. Genetics of congenital heart disease. Curr Cardiol Rev. 2010;6:91–97.
  • Srinivasan A, Bianchi DW, Huang H, et al. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am J Hum Genet. 2013;92:167–176.
  • Wapner RJ, Babiarz JE, Levy B, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol. 2015;212:332.e1–332.e9.
  • Korenberg JR, Chen XN, Schipper R, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci USA. 1994;91:4997–5001.
  • Springett A, Wellesley D, Greenlees R, et al. Congenital anomalies associated with trisomy 18 or trisomy 13: a registry-based study in 16 European countries, 2000–2011. Am J Med Genet. 2015;167: 3062–3069.
  • Farina A, Volinia S, Arcelli D, et al. Evidence of genetic underexpression in chorionic villi samples of euploid fetuses with increased nuchal translucency at 10–11 weeks’ gestation. Prenat Diagn. 2006;26:128–133.
  • Arcelli D, Farina A, Cappuzzello C, et al. Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening. Prenat Diagn. 2010;30:229–234.
  • Curti A, Lapucci C, Berto S, et al. Maternal plasma mRNA species in fetal heart defects: a potential for molecular screening. Prenat Diagn. 2016;36:738–743.
  • Liu N, Olson EN. MicroRNA regulatory networks in cardiovascular development. Dev Cell. 2010;18:510–525.
  • Condorelli G, Latronico MVG, Cavarretta E. MicroRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol. 2014;63:2177–2187.
  • Xie WQ, Zhou L, Chen Y, et al. Circulating microRNAs as potential biomarkers for diagnosis of congenital heart defects. World J Emerg Med. 2016;7:85–89.
  • Turchinovich A, Samatov TR, Tonevitsky AG, et al. Circulating miRNAs: cell–cell communication function? Front Genet. 2013;4:119.
  • Yu Z, Han S, Hu P, et al. Potential role of maternal serum microRNAs as a biomarker for fetal congenital heart defects. Med Hypotheses. 2011;76:424–426.
  • Zhu S, Cao L, Zhu J, et al. Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects. Clin Chim Acta. 2013;424:66–72.
  • Kehler L, Biro O, Lazar L, et al. Elevated hsa-miR-99a levels in maternal plasma may indicate congenital heart defects. Biomed Rep. 2015;3:869–873.
  • Coppola A, Romito A, Borel C, et al. Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications. Stem Cell Res. 2014;12:323–337.
  • Lázár L, Biró O, Rigó JJ, et al. Let-7c as potential maternal serum miRNA biomarker in fetal congenital heart defects. Biomed Pap. 2014;158:S8.
  • Scheuermann JC, Boyer LA. Getting to the heart of the matter: long non-coding RNAs in cardiac development and disease. Embo J. 2013;32:1805–1816.
  • He C, Hu H, Wilson KD, et al. Systematic characterization of long noncoding RNAs reveals the contrasting coordination of cis- and trans-molecular regulation in human fetal and adult hearts. Circ Cardiovasc Genet. 2016;9:110–118.
  • Song G, Shen Y, Zhu J, et al. Integrated analysis of dysregulated lncRNA expression in fetal cardiac tissues with ventricular septal defect. PLoS One. 2013;8:e77492.
  • Gu M, Zheng A, Tu W, et al. Circulating LncRNAs as novel, non-invasive biomarkers for prenatal detection of fetal congenital heart defects. Cell Physiol Biochem. 2016;38:1459–1471.
  • Llurba E, Syngelaki A, Sánchez O, et al. Maternal serum placental growth factor at 11–13 weeks’ gestation and fetal cardiac defects. Ultrasound Obstet Gynecol. 2013;42:169–174.
  • Llurba E, Sánchez O, Ferrer Q, et al. Maternal and foetal angiogenic imbalance in congenital heart defects. Eur Heart J. 2014;35:701–707.
  • Curti A, Zucchini C, De Maggio I, et al. Fetal cardiac defects and third-trimester maternal serum placental growth factor. Ultrasound Obstet Gynecol. 2015;45:751–752.
  • Chen L, Gu H, Li J, et al. Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects. Sci Rep. 2016;6:19248.
  • Farina A, Arcelli D. Congenital heart defects: is it time to explore maternal blood for a non-invasive genetic screening test? Ultrasound Obstet Gynecol. 2014;43:109–110.
  • Boyd HA, Basit S, Behrens I, et al. Association between fetal congenital heart defects and maternal risk of hypertensive disorders of pregnancy in the same pregnancy and across pregnancies clinical. Circulation. 2017;136:39–48.
  • Lalani SR. Other genomic disorders causing congenital cardiovascular malformations. In: Muenke M, Kruszka PS, Sable CA, Belmont JW, editors. Congenital heart disease: molecular genetics, principles of diagnosis and treatment. Basel: S. Karger AG; 2015. p. 112–120.
  • The NIFTY® Test – non-invasive prenatal testing by BGI. [Internet]. 2018 [cited 2018 Jul 13]. Available from: https://www.bgi.com/global/molecular-genetics/nifty-non-invasive-prenatal-testing/the-nifty-test-non-invasive-prenatal-testing/.
  • MaterniT® – non-invasive prenatal testing by Sequenom. [Internet]. 2018 [cited 2018 Jul 13]. Available from: https://www.sequenom.com/videos/what-is-noninvasive-prenatal-testing-nipt.
  • Panorama® Test – non-invasive prenatal testing by NATERA. [Internet]. 2018 [cited 2018 Jul 13]. Available from: https://www.natera.com/panorama-test.
  • Veri SeqTM – NIPT solution by Illumina. [Internet]. 2018 [cited 2018 Jul 13]. Available from: https://www.illumina.com/products/by-type/ivd-products/veriseq-nipt.html.
  • Harmony® – non-invasive prenatal test by Roche. [Internet]. 2018 [cited 2018 Jul 13]. Available from: https://www.illumina.com/products/by-type/ivd-products/veriseq-nipt.html.
  • PraenaTest® – non-invasive prenatal test by Lifecodexx. [Internet]. 2018 [cited 2018 Jul 13]. Available from: https://sequencing.roche.com/en/products-solutions/by-application/clinical/nipt.html.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.